News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,488 Results
Type
Article (39044)
Company Profile (279)
Press Release (646165)
Section
Business (203863)
Career Advice (1988)
Deals (35364)
Drug Delivery (85)
Drug Development (80802)
Employer Resources (168)
FDA (16086)
Job Trends (14802)
News (344541)
Policy (32436)
Tag
Academia (2530)
Alliances (49077)
Alzheimer's disease (1228)
Approvals (16018)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11533)
Biotechnology (200)
Breast cancer (119)
Cancer (1077)
Cardiovascular disease (97)
Career advice (1658)
Cell therapy (231)
Clinical research (64234)
Collaboration (384)
Compensation (197)
COVID-19 (2530)
C-suite (94)
Data (1119)
Diabetes (152)
Diagnostics (6138)
Earnings (84815)
Employer resources (146)
Events (109448)
Executive appointments (307)
FDA (16617)
Funding (346)
Gene therapy (176)
GLP-1 (574)
Government (4324)
Healthcare (18668)
Infectious disease (2614)
Inflammatory bowel disease (106)
Interviews (308)
IPO (16296)
Job creations (3623)
Job search strategy (1416)
Layoffs (412)
Legal (7853)
Lung cancer (170)
Manufacturing (176)
Medical device (13174)
Medtech (13179)
Mergers & acquisitions (19139)
Metabolic disorders (398)
Neuroscience (1503)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1474)
Obesity (228)
Opinion (179)
Patents (101)
People (56262)
Phase I (19948)
Phase II (28294)
Phase III (21096)
Pipeline (454)
Postmarket research (2553)
Preclinical (8487)
Radiopharmaceuticals (235)
Rare diseases (217)
Real estate (5891)
Regulatory (21517)
Research institute (2308)
Resumes & cover letters (349)
Southern California (1297)
Startups (3562)
United States (13376)
Vaccines (548)
Weight loss (166)
Date
Today (132)
Last 7 days (787)
Last 30 days (3730)
Last 365 days (35582)
2024 (32588)
2023 (40074)
2022 (51175)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35020)
2017 (32110)
2016 (31481)
2015 (37554)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (192)
Asia (37115)
Australia (6057)
California (3307)
Canada (1282)
China (247)
Colorado (143)
Connecticut (150)
Europe (79489)
Florida (455)
Georgia (116)
Illinois (338)
Indiana (195)
Kansas (96)
Maryland (573)
Massachusetts (2587)
Michigan (157)
Minnesota (271)
New Jersey (947)
New York (949)
North Carolina (696)
Northern California (1474)
Ohio (138)
Pennsylvania (839)
South America (1091)
Southern California (1297)
Texas (458)
Utah (90)
Washington State (357)
685,488 Results for "humacyte inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
FDA Needs More Time to Review Humacyte’s Blood Vessel Implant
Humacyte’s stock price dropped 18% in after-hours trading Friday after the company announced the FDA requires additional time to review its Biologic License Application. No reason was given for the delay or an updated decision date.
August 12, 2024
·
1 min read
·
Tristan Manalac
Bio NC
Humacyte to Participate at Upcoming Investor Conferences in May
Humacyte, Inc. today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, Dale Sander, Chief Financial Officer, and B.J. Scheessele, Chief Commercial Officer, will represent Humacyte at the following conferences in May.
May 13, 2024
·
2 min read
Bio NC
Humacyte to Present at the Jefferies Global Healthcare Conference
Humacyte, Inc. today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, in New York, NY on Thursday, June 6, 2024.
May 30, 2024
·
2 min read
Bio NC
Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)
Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, Human Acellular Vessels at commercial scale, announced the issuance of four new ICD-10-PCS codes by the U.S. Centers for Medicare & Medicaid Services ICD-10 Coordination and Maintenance Committee.
June 17, 2024
·
7 min read
Press Releases
Humacyte Third Quarter 2024 Financial Results and Business Update
November 8, 2024
·
16 min read
Press Releases
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
November 14, 2024
·
6 min read
Drug Development
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced the presentation of positive preclinical progress of its development of a potential treatment for type 1 diabetes at two scientific meetings.
June 25, 2024
·
6 min read
Bio NC
Humacyte, Inc. Announces Proposed Public Offering of Common Stock - February 29, 2024
Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that it has commenced an underwritten public offering of its common stock.
February 29, 2024
·
6 min read
Business
Humacyte First Quarter 2024 Financial Results and Business Update
Humacyte, Inc. announced financial results for the first quarter ended March 31, 2024 and highlighted recent accomplishments advancing the investigational Human Acellular Vessel™ closer to planned U.S. market launch.
May 10, 2024
·
14 min read
Bio NC
Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today announced the pricing of an underwritten public offering of 13,400,000 shares of its common stock at a public offering price of $3.00 per share.
February 29, 2024
·
6 min read
1 of 68,549
Next
